Oesophageal Adenocarcinoma Clinical Trials

3 recruiting

Oesophageal Adenocarcinoma Trials at a Glance

16 actively recruiting trials for oesophageal adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Taipei, New York, and Beijing. Lead sponsors running oesophageal adenocarcinoma studies include Merck Sharp & Dohme LLC, Bolt Biotherapeutics, Inc., and AstraZeneca.

Browse oesophageal adenocarcinoma trials by phase

Treatments under study

About Oesophageal Adenocarcinoma Clinical Trials

Looking for clinical trials for Oesophageal Adenocarcinoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oesophageal Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oesophageal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 1Phase 2

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled44 locationsNCT06445972
Recruiting
Phase 1Phase 2

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting
Phase 2

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
AstraZeneca100 enrolled70 locationsNCT07069712
Recruiting
Phase 1

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Gastroesophageal Adenocarcinoma
University of California, Irvine20 enrolled1 locationNCT05733689
Recruiting
Phase 2

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Esophageal AdenocarcinomaGastric AdenocarcinomaPancreas Adenocarcinoma+6 more
Yale University54 enrolled1 locationNCT07282912
Recruiting
Phase 2

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

MetastasesHER2 + Gastric CancerFirst Line Therapy+2 more
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest80 enrolled20 locationsNCT07176312
Recruiting
Not Applicable

Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer?

ExerciseTumor MicroenvironmentT Cells+1 more
University of Surrey50 enrolled1 locationNCT07375420
Recruiting
Phase 2

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
Canadian Cancer Trials Group168 enrolled18 locationsNCT06043427
Recruiting
Phase 1Phase 2

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

Gastroesophageal AdenocarcinomaGastric Cancer Adenocarcinoma Metastatic
Bolt Biotherapeutics, Inc.122 enrolled16 locationsNCT06921837
Recruiting
Phase 1

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Muscle-Invasive Bladder CarcinomaGastroesophageal Adenocarcinoma
Washington University School of Medicine32 enrolled1 locationNCT06529822
Recruiting
Phase 2

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Metastatic Colorectal CancerMetastatic Gastroesophageal AdenocarcinomaDPD Deficiency
UNICANCER73 enrolled21 locationsNCT06245356
Recruiting
Phase 2

A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.204 enrolled39 locationsNCT06767800
Recruiting
Phase 2

Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

Tumor MicroenvironmentOesophageal Adenocarcinoma
Amsterdam UMC, location VUmc14 enrolled2 locationsNCT06687876
Recruiting
Phase 2

Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ

Gastric AdenocarcinomaGastroesophageal Adenocarcinoma
Jiangsu Cancer Institute & Hospital30 enrolled1 locationNCT06985602
Recruiting

Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery

Gastric AdenocarcinomaOesophageal Adenocarcinoma
Imperial College London100 enrolled1 locationNCT06289374
Recruiting
Phase 1Phase 2

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Advanced Gastroesophageal Adenocarcinoma
Chinese PLA General Hospital42 enrolled3 locationsNCT05403242